Noble Life Sciences in partnership with NorthEast BioLab is hosting a webinar.

Overview:
The need for expedited drug development and efficient capital allocation has placed a justified emphasis on early in vivo testing for pharmacology and disease modulation. In this webinar, we would share actionable insights from our 100+ years of collective experience managing drug discovery, pharmacokinetics (PK), and biomarker testing studies.   

Agenda:

• Drug discovery screening process from target selectivity to potency in preclinical disease models
• In vivo proof-of-concept PK and Biomarker testing towards clinical efficacy based on drug exposure and biological response
• In vitro ADME (protein binding, metabolic stability, drug-drug interaction potential), pharmacodynamic (PD) biomarkers, and exposure-effect relationships
• PK/PD studies to assess drug safety margins, support dose selection for clinical trials, select endpoints, and benchmark pharmacological data

Featured Speakers

Dr. Stephen Horrigan CSO, Noble Life Sciences Dr. Horrigan is an accomplished molecular geneticist known for his contributions to the development of innovative approaches using genomic profiles and biomarkers to enhance drug discovery and development. He has strong expertise in the cellular control mechanisms of cancer and the use of biomarkers for the discovery and development of therapeutics and has multiple publications and patents in this area.

Mr. Ryan Sheeler, Sr. Scientist – PK/PD, NorthEast BioLab Mr. Sheeler has 20+ years experience in drug discovery, preclinical, and clinical PK/PD Analysis and Reporting. His broad-ranging expertise spans study/protocol design, LC-MS/MS assay, and SEND/SDTM data preparation and interpretation. He has worked across oncology, pain management, antimicrobials, mental health, and cardiac, respiratory, metabolic, and CNS disorders.